Recherchez et trouvez le CMO / CDMO dont vous avez besoin
Discover highly skilled partners for your drug development and manufacturing project.
Grèce
Adragos Pharma | Athens
Adragos Pharma
Spécialisé dans le développement de médicaments à valeur ajoutée et a été récemment mis à niveau avec les capacités HPAPI.
MARCHÉS: ANMAT (Argentina), EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS, SERVICES
COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), FDA (cGMP), NSF, NMPA (BPF de Chine), ISO, MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
Japon
Adragos Pharma | Kawagoe
Adragos Pharma
Notre usine offre la meilleure fabrication de comprimés et d’ampoules.
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS, SERVICES
MARCHÉS: EDE (UAE), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), FDA (cGMP)
TAILLE DU LOT: Grandes dimensions
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
RÉGION: APAC
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
France
Adragos Pharma | Livron
Adragos Pharma
Fabrication de liquides stériles et de suppositoires. Nous traitons plus de 100 molécules, la gestion des stupéfiants et les services d'analyse et de stabilité.
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (BPF DE L'UE), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
MARCHÉS: PMDA (Japan), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), MHRA (UK)
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
MARCHÉS: Turkish Health Authorities, ANVISA (Brazil), EMA (EU), SFDA (Saudi Arabia), NMPA (China), MHRA (UK)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (BPF DE L'UE), ANVISA (Brazil B-GMP), NMPA (BPF de Chine), SFDA (Saudi Food & Drug Authority), ISO, TITCK (Turkish Health Authorities), ICH
RÉGION: Europe
BSL (niveau de sécurité biologique): 3, 4
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
SUBSTANCES CONTRÔLÉES: High potential for abuse & medical use
OEB (bandes d´exposition professionnelle): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (L) Antineoplastic and immunomodulating agents
France
Cenexi
Cenexi
L'usine GMP sur un site de quatre hectares est située à 9 km à l'est de Paris. C'est un centre d'excellence pour les ampoules injectables.
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
MARCHÉS: EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), FDA (cGMP), NMPA (BPF de Chine), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain, Vétérinaire
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents
OEB (bandes d´exposition professionnelle): 1 / low-hazard (PDE > 10,000 µg/day)
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
CDM Lavoisier est spécialisée dans la fabrication d'ampoules en verre, de flacons en verre et d'ampoules en plastique (BFS).
Location available after registration
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
CMO combinant des installations avancées, un contrôle qualité rigoureux et un personnel expert pour fournir des solutions fiables, conformes et innovantes.
Location available after registration
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
Laboratoire de recherche et développement sous contrat (CRDO) basé aux États-Unis qui fournit des services de développement de produits pharmaceutiques.
Location available after registration
More facilities on the network
Register to unlock the full catalog with contact details and locations.
+8 more facilities
Create free accountSuggested Results
These facilities match your main criteria but not all optional filters.
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
Solutions pour les programmes de distribution non virale
Location available after registration
Espagne
Laboratorios Grifols | Murcia Plant
Grifols International
Solutions de fabrication stériles (petites molécules) en sacs souples.
MARCHÉS: ANMAT (Argentina), ANVISA (Brazil), FDA (USA), EMA (EU), MFDS (South Korea), TGA (Australia)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: ISP (Chile BPM), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, INVIMA, Santé Canada (Canada GMP), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain, Vétérinaire
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (M) Musculoskeletal system, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (N) Nervous system
Espagne
Laboratorios Grifols | Barcelona Plant
Grifols International
Solutions de fabrication stériles (petites molécules) en poches souples et flacons.
MARCHÉS: ANMAT (Argentina), ANVISA (Brazil), PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), TGA (Australia), Health Canada (Canada), MHRA (UK)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: ISP (Chile BPM), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, INVIMA, Santé Canada (Canada GMP), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain, Vétérinaire
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism, (N) Nervous system
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
Site de développement intégré et de fabrication cGMP.
Location available after registration
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
—
Location available after registration
Limited view
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
Fabrication d'ARNm et de LNP et remplissage et finition.
Location available after registration